Wize Pharma Inc. (WIZP) Starts Presentation at 9th Annual LD Micro Invitational
Wize Pharma (OTCQB: WIZP) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including CCh and Sjögren's syndrome (Sjögren's). Wize's strategy involves engaging local or multinational distributors to handle the distribution of LO2A. Wize has finished a Phase II trial of LO2A for patients with CCH and is currently conducting a phase IV study for LO2A for DES in patients with Sjögren's. For more information, visit…







